Healthcare / BiotechnologyTokyo
$451.00
+30.00 (+7.13%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-1.7B · quality 42.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-702.2%
↓Gross Margin
67.0%
↑Debt/Equity
2.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-25.3%
FCF CAGR
—
FCF margin
-374.5%
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $579.1M · net income $-2.17B · FCF $-2.17B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $579.1M | $579.1M | $636.2M | $1.63B | $1.39B |
| Net Income | $-2.17B | $-2.17B | $-2.18B | $-1.15B | $-1.35B |
| EBITDA | $-2.16B | $-2.16B | $-2.14B | $-1.09B | $-1.28B |
| EPS | -113.62 | -113.62 | -121.64 | -68.62 | -99.10 |
| Gross Margin | 67.0% | 67.0% | 73.2% | 89.2% | 87.6% |
| Operating Margin | -358.3% | -358.3% | -326.3% | -68.7% | -91.6% |
| Net Margin | -375.0% | -375.0% | -342.4% | -70.9% | -97.3% |
| Balance Sheet | |||||
| Debt/Equity | 2.31 | 2.31 | 0.02 | 0.05 | 0.08 |
| Current Ratio | 16.12 | 16.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.17B | $-2.17B | $-1.39B | $-1.69B | $-834.4M |
| Returns | |||||
| ROE | -702.2% | -702.2% | -88.0% | -29.7% | -37.1% |
| Valuation | |||||
| P/B | 27.87 | 27.87 | 2.17 | 2.22 | 1.90 |
| Growth & Yield | |||||
| Revenue Growth | -9.0% | -9.0% | -60.9% | 17.2% | — |
| EPS Growth | 6.6% | 6.6% | -77.3% | 30.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+56.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-121.64 → -113.62
Residual
+56.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.